M42, Cleveland Clinic Abu Dhabi, Gunma University in Japan to drive innovation in heavy ion therapy for cancer treatment
ABU DHABI (ALETIHAD)M42 and Cleveland Clinic Abu Dhabi, have signed a Memorandum of Cooperation (MoC) with Gunma University in Japan to accelerate research and innovation in heavy ion therapy, one of the most advanced and precise forms of radiation therapy for cancer treatment.This collaboration, which took place during M42 and Cleveland Clinic Abu Dhabi's recent delegation visit to Japan, will see the three entities exchange knowledge, expertise, and research to deepen scientific understanding, and to broaden the clinical applications of heavy ion therapy.The collaboration builds on M42 and Cleveland Clinic Abu Dhabi's recent partnership with Toshiba Energy Systems & Solutions Corporation (Toshiba ESS) to establish the region's first heavy ion therapy facility in Abu Dhabi.This initiative will introduce one of the world's most innovative cancer treatment technologies to the Middle East, positioning Abu Dhabi as a centre of excellence in oncology and precision medicine.With no heavy ion therapy centre within a five-hour flight of the UAE, the upcoming facility—strategically located on the Cleveland Clinic Abu Dhabi campus, adjacent to the Fatima bint Mubarak Centre, the region's first-of-its-kind comprehensive cancer centre—will enhance access to this treatment for patients across the Middle East.Dr. Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, said, "At Cleveland Clinic Abu Dhabi, our vision is to bring the most advanced, evidence-based treatments to our patients, and this partnership with Gunma University exemplifies that commitment. By combining our clinical expertise with Gunma's decades of leadership in heavy ion therapy, we are not only advancing scientific knowledge but also laying the groundwork for a new era of cancer care in the region."President Ishizaki Yasuki at Gunma University, commented, "Gunma University has long been committed to advancing the science of heavy ion therapy through rigorous research and clinical innovation."He added, "Partnering with M42 will enable us to expand the reach of this transformative therapy, fostering international collaboration and ensuring that more patients worldwide benefit from the latest advancements in cancer treatment."
Gunma University has been at the forefront of radiation oncology and nuclear medicine in Japan for decades. The Gunma University Heavy Ion Medical Centre (GHMC), established in 2005, has been instrumental in refining heavy ion radiotherapy by integrating radiation biology, clinical studies, and cutting-edge treatment technologies.
Source: Aletihad - Abu Dhabi
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Dubai Eye
a day ago
- Dubai Eye
Abu Dhabi launches newborn genetic testing programme
Abu Dhabi has rolled out a newborn genetic screening programme for Emirati nationals across several hospitals, to enable early detection and diagnosis of genetic conditions. The Newborn Genetic Screening Programme offers whole genome sequencing to screen more than 815 treatable childhood genetic conditions, including metabolic disorders, immunodeficiencies, hematologic conditions, and rare diseases such as spinal muscular atrophy. Using genomics and artificial intelligence (AI), the first phase of the programme has been implemented as a voluntary option at Kanad Hospital and Danat Al Emarat Hospital, in partnership with M42. The initiative is planned to be expanded across all maternity hospitals to screen UAE nationals and children of Emirati mothers born in the emirate. By collecting and testing cord blood samples at birth, with parental consent, healthcare providers can identify conditions that may not be apparent at birth but could significantly affect a child's health if treatment is delayed. Results are reported within 21 days, and parents will receive genetic counselling and be referred to multidisciplinary specialists if any actionable findings are identified. 'Through early detection, personalised care and strategic foresight, we are building a future of healthier generations and reinforcing Abu Dhabi's position as a global leader in proactive, precision healthcare," said Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi. To support the rollout of the programme, DoH conducted a workshop to review the gene panel and patient journey with specialists from stakeholders across Abu Dhabi. DoH also collaborated with M42 to train 16 paediatricians and neonatologists across three maternity hospitals, Corniche Hospital, Danat Al Emarat and Kanad Hospital, on genetic counselling practices and the importance of newborn genetic screening. These initiatives aim to reduce the prevalence of genetic diseases, inform reproductive choices, facilitate access to early intervention, and empower families with vital health information, fostering a future where personalised, preventative healthcare is the standard. The Newborn Genetic Screening Programme is one of several initiatives that have been made possible by the Emirati Genome Programme, such as the Premarital Screening Programme, harnessing the power of genomics and latest technologies to promote informed decisions. These efforts pave the way forward for more precise and effective treatments, ensuring the long-term health and wellbeing of future generations of Emiratis.
TAG 91.1
a day ago
- TAG 91.1
Abu Dhabi launches newborn genetic testing programme
Abu Dhabi has rolled out a newborn genetic screening programme for Emirati nationals across several hospitals, to enable early detection and diagnosis of genetic conditions. The Newborn Genetic Screening Programme offers whole genome sequencing to screen more than 815 treatable childhood genetic conditions, making it one of the most comprehensive genetic screening programmes for newborns in the world. Using genomics and artificial intelligence (AI), the first phase of the programme has been implemented as a voluntary option at Kanad Hospital and Danat Al Emarat Hospital, in partnership with M42. The initiative is planned to be expanded across all maternity hospitals to screen UAE Nationals and children of Emirati mothers born in the emirate, further strengthening Abu Dhabi's leadership in preventive healthcare and precision medicine. By collecting and testing cord blood samples at birth, with parental consent, healthcare providers can identify conditions that may not be apparent at birth but could significantly affect a child's health if treatment is delayed. The conditions screened under the programme include metabolic disorders, immunodeficiencies, hematologic conditions, and rare diseases such as spinal muscular atrophy, which is treatable by gene therapy. Results are reported within 21 days, and parents will receive genetic counselling and be referred to multidisciplinary specialists if any actionable findings are identified. Her Excellency Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: 'Healthcare begins long before symptoms appear, and today, empowered by science and technology, we can act earlier than ever before." Dr. Mohamed Al Ameri, Acting Director of Genome and Biobank Division, Department of Health – Abu Dhabi said: 'As we work to integrate genomics into our preventative healthcare infrastructure, we aim to expand this initiative to all maternity hospitals in the emirate, demonstrating how genomics can reshape healthcare, shifting from a one-size-fits-all model to a precise, proactive, and personalised approach that improves patient outcomes.' To support the rollout of the programme, DoH conducted a workshop to review the gene panel and patient journey with specialists from stakeholders across Abu Dhabi. DoH also collaborated with M42 to train 16 paediatricians and neonatologists across three maternity hospitals, Corniche Hospital, Danat Al Emarat and Kanad Hospital, on genetic counselling practices and the importance of newborn genetic screening. Early detection through this enhanced screening programme allows for timely medical intervention and aligns with Abu Dhabi's broader strategy to integrate genomics into various aspects of family health, including premarital screening and genetic counselling, thus creating a comprehensive, family-centred care ecosystem. These initiatives aim to reduce the prevalence of genetic diseases, inform reproductive choices, facilitate access to early intervention, and empower families with vital health information, fostering a future where personalised, preventative healthcare is the standard. The Newborn Genetic Screening Programme is one of several initiatives that have been made possible by the Emirati Genome Programme, such as the Premarital Screening Programme, harnessing the power of genomics and latest technologies to promote informed decisions. These efforts pave the way forward for more precise and effective treatments, ensuring the long-term health and wellbeing of future generations of Emiratis.
Al Etihad
a day ago
- Al Etihad
Department of Health – Abu Dhabi launches Newborn Genetic Screening Programme
18 Aug 2025 11:10 ABU DHABI (ALETIHAD)The Department of Health - Abu Dhabi (DoH), in alignment with the Emirati Genome Council's vision to realise a national shift towards personalised, precision healthcare, has launched the Newborn Genetic Screening Programme. The initiative translates Abu Dhabi's commitment to pioneering genomics-driven medicine that enables early detection and diagnosis, tailored interventions, and improved health outcomes for future Newborn Genetic Screening Programme offers whole genome sequencing to screen more than 815 treatable childhood genetic conditions, making it one of the most comprehensive genetic screening programmes for newborns the power of genomics and artificial intelligence (AI), the first phase of the programme has been implemented as a voluntary option at Kanad Hospital and Danat Al Emarat Hospital, in partnership with M42. The initiative is planned to be expanded across all maternity hospitals to screen UAE Nationals and children of Emirati mothers born in the emirate, further strengthening Abu Dhabi's leadership in preventive healthcare and precision collecting and testing cord blood samples at birth, with parental consent, healthcare providers can identify conditions that may not be apparent at birth but could significantly affect a child's health if treatment is delayed. The conditions screened under the programme include metabolic disorders, immunodeficiencies, hematologic conditions, and rare diseases such as spinal muscular atrophy, which is treatable by gene Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: 'Healthcare begins long before symptoms appear, and today, empowered by science and technology, we can act earlier than ever added: 'This programme reflects Abu Dhabi's commitment to leveraging innovation to serve our community, starting from the first days of life. Through early detection, personalised care, and strategic foresight, we are building a future of healthier generations and reinforcing Abu Dhabi's position as a global leader in proactive, precision healthcare.'Dr. Mohamed Al Ameri, Acting Director of Genome and Biobank Division, Department of Health – Abu Dhabi said: 'As we work to integrate genomics into our preventative healthcare infrastructure, we aim to expand this initiative to all maternity hospitals in the emirate, demonstrating how genomics can reshape healthcare, shifting from a one-size-fits-all model to a precise, proactive, and personalised approach that improves patient outcomes.'To support the rollout of the programme, DoH conducted a workshop to review the gene panel and patient journey with specialists from stakeholders across Abu also collaborated with M42 to train 16 paediatricians and neonatologists across three maternity hospitals, Corniche Hospital, Danat Al Emarat and Kanad Hospital, on genetic counselling practices and the importance of newborn genetic comprehensive workshops were conducted for obstetricians, midwives, nurses and technical teams from these are reported within 21 days, and parents will receive genetic counselling and be referred to multidisciplinary specialists if any actionable findings are detection through this enhanced screening programme allows for timely medical intervention and aligns with Abu Dhabi's broader strategy to integrate genomics into various aspects of family health, including premarital screening and genetic counselling, thus creating a comprehensive, family-centred care ecosystem. These initiatives aim to reduce the prevalence of genetic diseases, inform reproductive choices, facilitate access to early intervention, and empower families with vital health information, fostering a future where personalised, preventative healthcare is the standard. The Newborn Genetic Screening Programme is one of several initiatives that have been made possible by the Emirati Genome Programme, such as the Premarital Screening Programme, harnessing the power of genomics and the latest technologies to promote informed decisions. These efforts pave the way forward for more precise and effective treatments, ensuring the long-term health and well-being of future generations of Emiratis. Source: Aletihad - Abu Dhabi
